drug
benzoyl peroxide
Marketedupdated 5mo agoby Galderma Laboratories LP
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying benzoyl peroxide
- —Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- N/ARadiofrequency Treatment Versus Topical Therapy for Facial Acne Vulgaris
- phase2Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
- phase1A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
- phase3Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
- phase4Profiling the Skin Microbiome in Response to Altreno in Acne Patients
- N/AClinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations
- phase3Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 3, 2028
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (25)
- May 23, 2041formulationUS 12257348
- Dec 27, 2040method-of-use (U-3356)US 11628155
- Dec 27, 2040method-of-use (U-3356)US 12295935
- Aug 18, 2040method-of-use (U-3356)US 11426378
- Feb 19, 2040formulationUS 10933046
- Feb 19, 2040method-of-use (U-3356)US 10945987
- Feb 19, 2040method-of-use (U-3356)US 11541026
- Feb 19, 2040method-of-use (U-3357)US 11865100
- Feb 19, 2040method-of-use (U-3356)US 11877997
- Feb 19, 2040method-of-use (U-3947)US 11986456
- Nov 27, 2032formulationUS 9687465
- Aug 5, 2029formulationUS 82884342.8y
- Aug 5, 2029formulationUS 82884342.8y
- Jun 3, 2029formulationUS 101371422.7y
- Jun 3, 2029formulationUS 102200492.7y
- Jun 3, 2029formulationUS 102200492.7y
- Jun 3, 2029method-of-use (U-916)US 106249182.7y
- Jun 3, 2029method-of-use (U-124)US 86636992.7y
- Jun 3, 2029method-of-use (U-124)US 88950702.7y
- Jun 3, 2029formulationUS 90788702.7y
- Jun 3, 2029formulationUS 95047042.7y
- Jun 3, 2029formulationUS 95612082.7y
- Aug 8, 2028formulationUS 98681031.8y
- Feb 3, 2028formulationUS 121569461.3y
- Feb 3, 2028formulationUS 123503821.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that